Compare TeraWulf Inc (WULF) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TeraWulf Inc vs State Street SPDR S&P Biotech ETF — how do they compare? TeraWulf Inc trades at $13.67 (market cap $6.81B), while State Street SPDR S&P Biotech ETF trades at $154.12 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TeraWulf Inc for 17 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| WULF | XBI | |
|---|---|---|
Market Cap | $6.81B | $10.11B |
Volume | 45,841,998 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $28.98 | $169.55 |
52-Week Low | $10.99 | $104.99 |
Typical Hold Time | 17 Days | 37 Days |
Enterprise Value | $9.43B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TeraWulf (WULF) trades at $13.73, down 4.65% today, amid bearish technical signals despite unanimous analyst optimism. The stock shows severe fundamental strain with negative profit margins (-1,179.94% net income margin) and consecutive earnings misses, though revenue remains stable near $168M. Recent news highlights the company's pivot to AI data center operations, with UBS initiating bullish coverage citing long-term power access advantages.
While analyst consensus points to significant upside (average target $34.92), the stock faces substantial execution risks in its AI transition amid persistent cash burn. Investors must weigh Wall Street's optimistic price targets against the company's current negative profitability and high valuation multiples in a competitive infrastructure sector.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
